November 04, 2024
Developing treatments for people with mental health conditions
October 14, 2024
Boehringer Ingelheim and WHO Foundation join forces to promote equitable access to healthcare
September 27, 2024
Boehringer Ingelheim partners with NCD Alliance to target Non-Communicable Diseases in underserved communities
July 03, 2024
Boehringer Ingelheim advances SIRPα immuno-oncology program
July 01, 2024
Phase 1 start for novel triple agonist obesity treatment
May 22, 2024
Partnership for first-in-class cancer and CRM treatments
March 11, 2024
New partnership to develop schizophrenia treatments
February 08, 2024
Boehringer Ingelheim and CBmed join forces to translate novel cancer therapy approaches faster into new medicines for patients
January 09, 2024
Kicking off 2024 with five new R&D partnerships
January 09, 2024
New study paves the way for liver cirrhosis treatments
January 03, 2024
Partnership for new liver disease treatments with Ribo
November 28, 2023
Partnership with IBM to accelerate new antibody therapies
October 02, 2023
Boehringer Ingelheim and ZEISS join forces to early detect eye diseases and prevent vision loss
May 09, 2023
IL-11 inhibitor antibody clinical development launched
January 09, 2023
New cancer therapeutics collaboration with 3T Bio
December 19, 2022
New digital Tx collab with Click
October 20, 2022
AI and Data Science Fellowship with University of Tuebingen
July 06, 2022
Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
June 14, 2022
Option to Acquire Trutino Biosciences
June 02, 2022
A*STAR antibodies bolster ADC and T-Cell engager development
May 11, 2022
Boehringer Ingelheim’s signal analytics technology is acquired by ArisGlobal
Boehringer Ingelheim’s signal analytics technology is acquired by ArisGlobal
March 29, 2022
Boehringer Ingelheim selects Veeva Development Cloud worldwide to bring innovative therapies to patients faster
March 01, 2022
Boehringer Ingelheim and Lifebit announce partnership to capture transformational value of health data
October 27, 2021
Mental health collaboration with King’s College London
October 26, 2021
Partnership to Develop Urea Cycle Disorders Therapy
October 19, 2021
Cystic Fibrosis Gene Therapy Takes to Next step
October 06, 2021
Boehringer Ingelheim inaugurates biopharmaceutical production facility in Vienna, Austria
September 21, 2021
Acquisition to advance cancer immunology research
September 16, 2021
Clinical collaboration with Amgen on KRAS
May 10, 2021
Biomedical Data Science Fellowship Program with Yale
April 14, 2021
Expansion of Collaboration with MD Anderson to Explore KRAS and TRAILR2 Compounds in Lung Cancer
March 16, 2021
Collaboration with the LIBD to Develop Centrally Acting COMT Inhibitors
March 01, 2021
Boehringer Ingelheim and Gubra Join Forces to Identify and Validate Innovative Peptides for the Treatment of Obesity
January 12, 2021
Collaboration with Enara Bio on Cancer Immunotherapies
January 12, 2021
Boehringer Ingelheim partners with PetMedix
December 10, 2020
Boehringer Ingelheim to acquire NBE-Therapeutics
Media Contacts
Head of Global Media Relations
E-Mail:
harro.ten_wolde@boehringer-ingelheim.com
Phone Number:
+49 (6132) 77-181352
Senior Media Relations Manager
E-Mail:
tereza.urbankova@boehringer-ingelheim.com
Phone Number:
+49 (6132) 77-184817
Senior Media Relations Manager
E-Mail:
mark_william.valentiner@boehringer-ingelheim.com
Tel.: +49 (6132) 77-170136
Media Relations Manager
E-Mail:
valerie-chiara.nestle@boehringer-ingelheim.com
Phone Number:
+49 (7351) 54-175075
Head of Human Pharma Communications
E-Mail:
anthonia.aboyeji@boehringer-ingelheim.com
Phone Number:
+49 (6132) 77-172370
Head of Animal Health Communications
E-Mail:
Heidi.DeWit-Sommerfeld@boehringer-ingelheim.com
Phone Number:
+49 (6132) 77-171799
Head of Innovation Unit Communications
E-Mail: camilla.krogh_lauritzen@boehringer-ingelheim.com
Phone Number: +45 2272 4806